1. 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two. Issue 1 (November 2016) Authors: Ager, Casey; Reilley, Matthew; Nicholas, Courtney; Bartkowiak, Todd; Jaiswal, Ashvin; Curran, Michael; Albershardt, Tina; Bajaj, Anshika; Archer, Jacob; Reeves, Rebecca; Ngo, Lisa; Berglund, Peter; ter Meulen, Jan; Denis, Caroline; Ghadially, Hormas; Arnoux, Thomas; Chanuc, Fabien; Fuseri, Nicola... Journal: Journal for immunotherapy of cancer Issue: Volume 4:Issue 1(2016) Page Start: 107 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two. Issue 1 (November 2016) Authors: Ager, Casey; Reilley, Matthew; Nicholas, Courtney; Bartkowiak, Todd; Jaiswal, Ashvin; Curran, Michael; Albershardt, Tina; Bajaj, Anshika; Archer, Jacob; Reeves, Rebecca; Ngo, Lisa; Berglund, Peter; ter Meulen, Jan; Denis, Caroline; Ghadially, Hormas; Arnoux, Thomas; Chanuc, Fabien; Fuseri, Nicola... Journal: Journal for immunotherapy of cancer Issue: Volume 4:Issue 1(2016) Page Start: 107 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two: National Harbor, MD, USA. 9-13 November 2016. (16th November 2016) Authors: Ager, Casey; Reilley, Matthew; Nicholas, Courtney; Bartkowiak, Todd; Jaiswal, Ashvin; Curran, Michael; Albershardt, Tina C.; Bajaj, Anshika; Archer, Jacob F.; Reeves, Rebecca S.; Ngo, Lisa Y.; Berglund, Peter; ter Meulen, Jan; Denis, Caroline; Ghadially, Hormas; Arnoux, Thomas; Chanuc, Fabien; Fu... Journal: Journal for immunotherapy of cancer Issue: Volume 4(2016)Supplement 1 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. 369 Safety and pharmacodynamic activity of ATOR-1015, a CTLA-4 x OX40 bispecific antibody, in a phase 1 dose escalation study of patients with advanced solid malignancies. (10th December 2020) Authors: Yachnin, Jeffrey; Ullenhag, Gustav; Carneiro, Ana; Nielsen, Dorte; Rohrberg, Kristoffer Staal; Kvarnhammar, Anne Månsson; Schultz, Lena; Bågeman, Erika; Bågeman, Erika; Wennersten, Camilla; Russell, Charlotte; Russell, Charlotte Journal: Journal for immunotherapy of cancer Issue: Volume 8(2020)Supplement 3 Page Start: A225 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. 369 Safety and pharmacodynamic activity of ATOR-1015, a CTLA-4 x OX40 bispecific antibody, in a phase 1 dose escalation study of patients with advanced solid malignancies. (9th November 2020) Authors: Yachnin, Jeffrey; Ullenhag, Gustav; Carneiro, Ana; Nielsen, Dorte; Rohrberg, Kristoffer Staal; Kvarnhammar, Anne Månsson; Schultz, Lena; Bågeman, Erika; Bågeman, Erika; Wennersten, Camilla; Russell, Charlotte; Russell, Charlotte Journal: Journal for immunotherapy of cancer Issue: Volume 8(2020)Supplement 3 Page Start: A394 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. 853 Profiling of donor-specific immune effector signatures in response to rituximab in a human whole blood loop assay using blood from CLL patients. (9th November 2020) Authors: Eltahir, Mohamed; Fletcher, Erika; Dynesius, Linn; Jarblad, Justina; Lord, Martin; Olsson, Ida; Zekarias, Mikaela; Yu, Xiaojie; Cragg, Mark; Hammarstom, Caroline; Levedahl, Kerstin Hamberg; Höglund, Martin; Ullenhag, Gustav; Mattsson, Mattias; Mangsbo, Sara Journal: Journal for immunotherapy of cancer Issue: Volume 8(2020)Supplement 3 Page Start: A906 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. 853 Profiling of donor-specific immune effector signatures in response to rituximab in a human whole blood loop assay using blood from CLL patients. (9th November 2020) Authors: Eltahir, Mohamed; Fletcher, Erika; Dynesius, Linn; Jarblad, Justina; Lord, Martin; Olsson, Ida; Zekarias, Mikaela; Yu, Xiaojie; Cragg, Mark; Hammarstom, Caroline; Levedahl, Kerstin Hamberg; Höglund, Martin; Ullenhag, Gustav; Mattsson, Mattias; Mangsbo, Sara Journal: Journal for immunotherapy of cancer Issue: Volume 8(2020)Supplement 3 Page Start: A508 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. A systematic search strategy identifies cubilin as independent prognostic marker for renal cell carcinoma. Issue 1 (December 2017) Authors: Gremel, Gabriela; Djureinovic, Dijana; Niinivirta, Marjut; Laird, Alexander; Ljungqvist, Oscar; Johannesson, Henrik; Bergman, Julia; Edqvist, Per-Henrik; Navani, Sanjay; Khan, Naila; Patil, Tushar; Sivertsson, Åsa; Uhlén, Mathias; Harrison, David; Ullenhag, Gustav; Stewart, Grant; Pontén, Fredrik Journal: BMC cancer Issue: Volume 17:Issue 1(2017) Page Start: 1 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Cancer treatment of today in view of the Nobel Prize. (2nd October 2018) Authors: Ullenhag, Gustav Journal: Upsala journal of medical sciences Issue: Volume 123:Number 4(2018) Page Start: 205 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Complete and long-lasting clinical responses in immune checkpoint inhibitor-resistant, metastasized melanoma treated with adoptive T cell transfer combined with DC vaccination. (1st January 2020) Authors: Lövgren, Tanja; Wolodarski, Maria; Wickström, Stina; Edbäck, Ulrika; Wallin, Mette; Martell, Eva; Markland, Katrin; Blomberg, Pontus; Nyström, Maria; Lundqvist, Andreas; Jacobsson, Hans; Ullenhag, Gustav; Ljungman, Per; Hansson, Johan; Masucci, Giuseppe; Tell, Roger; Poschke, Isabel; Adamson, Lar... Journal: Oncoimmunology Issue: Volume 9:Number 1(2020) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗